nach oben

Current Oncology Reports

Erschienen in:

01.11.2010

Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management

verfasst von: Maurie Markman

Erschienen in: Current Oncology Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Individual randomized phase 3 trials and meta-analyses of previously published studies have provided support for the general concept of the clinical utility of extending the duration of antineoplastic drug therapy in an effort to prolong (“maintain”) a favorable clinical state. This commentary briefly reviews data from several of these reports.

Maughan TS, James RD, Kerr DJ, et al.: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003, 361:457–464.CrossRefPubMed

Hall GD, Brown JM, Coleman RE, et al.: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 2004, 91:621–626.CrossRefPubMed

Varia MA, Stehman FB, Bundy BN, et al.: Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:2849–2855.CrossRefPubMed

Bolis G, Danese S, Tateo S, et al.: Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 2006, 16(Suppl 1):74–78.CrossRefPubMed

Pfisterer J, Weber B, Reuss A, et al.: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A Gynecologic Cancer Intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006, 98:1036–1045.CrossRefPubMed

Greene MH, Boice JD Jr, Greer BE, et al.: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 1982, 307:1416–1421.CrossRefPubMed

Travis LB, Curtis RE, Boice JD Jr, et al.: Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996, 56:1564–1570.PubMed

Travis LB, Holowaty EJ, Bergfeldt K, et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340:351–357.CrossRefPubMed

Owonikoko TK, Ramalingam SS, Belani CP: Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res 2010, 16:2496–2504.CrossRefPubMed

10.

Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521–529.CrossRefPubMed

11.

Ciuleanu T, Brodowicz T, Zielinski C, et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432–1440.CrossRefPubMed

12.

Muss HB, Case LD, Richards F, et al.: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 1991, 325:1342–1348.CrossRefPubMed

13.

Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21:2460–2465.CrossRefPubMed

14.

Markman M, Liu PY, Moon J, et al.: Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009, 114:195–198.CrossRefPubMed

15.

Burger RA, Brady MF, Bookman MA, et al.: Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study. J Clin Oncol 2010, 28(Suppl):LBA1.

16.

Bozcuk H, Artac M, Ozdogan M, Savas B: Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005, 104:2650–2657.CrossRefPubMed

17.

Soon YU, Stockler MR, Askie LM, et al.: Duration of chemotherapy for advanced non-small-cell lung cancer: A systemic review and meta-analysis of randomized trials. J Clin Oncol 2009, 27:3277–3283.CrossRefPubMed

18.

Miller KD, Sweeney CJ, Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195–1206.PubMed

19.

Markman M, Hakes T, Barakat R, et al.: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996, 14:796–799.PubMed

20.

Rohl J, Kushner D, Markman M: Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol 2001, 81:201–205.CrossRefPubMed

21.

von Gruenigen V, Karlen JR, Waggoner SE: A case of chronic paclitaxel administration in ovarian cancer. Gynecol Oncol 2003, 89:532–535.CrossRef

22.

Markman M: Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol 2006, 100:229–230.CrossRefPubMed

Titel: Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management
verfasst von: Maurie Markman
Publikationsdatum: 01.11.2010
Verlag: Current Science Inc.
Erschienen in: Current Oncology Reports / Ausgabe 6/2010
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0121-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data

Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?

Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Is Maintenance Rituximab Now Ready for PRIMA-Time?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie